Cornerstone Robotics closed an oversubscribed financing round worth approximately $200 million. The financing included investments from a global strategic investor, some global institutional or sovereign wealth funds and existing shareholders. Hong Kong–based Cornerstone plans to use funds to accelerate commercialization efforts and continue innovating in surgical robotics.
Cornerstone develops an autonomous endoscopic robotic surgery platform. It equipped its laparoscopic surgical robot with AI-powered embodied intelligence. In August, the company announced a breakthrough in surgical automation for the platform in collaboration with researchers at the Chinese University of Hong Kong (CUHK).
Related: Synchron secures $200m to advance Stentrode platform commercialisation
Founded in 2019, Cornerstone Robotics develops the Sentire surgical system, which holds NMPA approval in China. The company has brought it into clinical use in hospitals across the Chinese mainland, Hong Kong and Europe, according to a news release.
The company designed Sentire to ensure consistent, precise movements, minimising variability and optimizing outcomes. It features cutting-edge control algorithms and real-time feedback to give surgeons confidence in every procedure. Sentire has a responsive design, allowing surgeons to perform complex procedures with fluid, natural movements, enhancing both precision and efficiency.
By minimizing resistance and optimising ergonomics, Sentire ensures a refined, user-friendly experience that elevates surgical performance, the company says. It has an integrated cold light source and advanced automation algorithms with an anti-fog feature for optimal visibility. The company says it designed Sentire for longevity, flexibility and durability with instruments that support a range of functions. Current indications include urology, gynecology, gastrointestinal surgery, thoracic surgery and hepato-biliary-pancreatic surgery.
Cornerstone said the $200 million in funding accelerates its mission to make safe, efficient and accessible surgical robotic technologies available to healthcare providers worldwide.
“The year 2025 marks an important milestone in the development journey of Cornerstone Robotics. We extend our heartfelt gratitude to our new and existing shareholders for their trust and support. This represents not only recognition of the successful clinical application of our innovations, but also strong confidence in Cornerstone Robotics’ long-term growth,” said Samuel Au, founder and CEO of Cornerstone Robotics. “Moving forward, we will remain committed to innovation-driven development and deepen our global presence, bringing safe, high-quality, and accessible surgical robotic solutions to patients and healthcare providers around the world.”
